Nonalcoholic Steatohepatitis

DUR-928 compound continues phase 1 clinical trials

A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...

May 19, 2015
popularity20 comments 0

Researchers link liver disease and drug metabolism

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications ...

Jul 09, 2015
popularity12 comments 0

NASH-linked changes impact metformin pharmacokinetics

(HealthDay)—Nonalcoholic steatohepatitis (NASH)-associated changes in liver function affect kidney transporter expression and metformin pharmacokinetics, according to an experimental study published online May 27 in Diabetes ...

Jun 04, 2015
popularity6 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Erasing unpleasant memories with a genetic switch

Researchers from KU Leuven (Belgium) and the Leibniz Institute for Neurobiology (Germany) have managed to erase unpleasant memories in mice using a 'genetic switch'. Their findings were published in Biological Psychiatry.